Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b … – News-Medical.net
eYugoslavia.comAbbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b …News-Medical.netToday Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) announced additional results from the SELECT Phase 2b trial, the first of two registr…